1Zhao Q,He Y,Alespeiti G,et al.A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5.Virology,2004,326(2):299-309.
2Han Z,Sinpson JT,Fivash M J,et al.Identification and characterization of peptides that bind to cyanovirin-N,a potent human immunodeficiency virus-inactivating protein.Peptides,2004,25(4):551-561.
3Bar S,Alizon M.RoLe of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.J Virol,2004,78(2):811-820.
4De Clercq E.The emerging role of fusion inhibitors in HIV infection.Drugs R D,1999,2(5):321-331.
5For the AMD3100 HIV Study Group.Safety,pharmacokinetics,and antiviral activity of AMD3100,a selective CXCR4 receptor inhibitor,in HIV-1 infection.J Acquir Immune Defic Syndr,2004,37(2):1253-1262.
6Hirschel B.Simplified treatments for HIV infection.Ther Umsch,2004,61 (10):619-623.
7Sang MS.Initiation of antiretroviral therapy:implications of recent findings.Top HIV Med,2004,12(3):83-88.
8De Clercq E.Antiviral drugs in current clinical use.J Clin Virol,2004,30(2):115-133.
9Perry CM,Faulds D.Lamivudine:A review of its antiviral activity,pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.Drugs,1997,53(4):657-680.
